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We have  already  reported  1 the results  of our  studies with subcu- 
taneous  injections  of  immune  serum  in  spirocha~tosis  icteroh~emor- 
rhagica.  In the present article are presented the results of injections 
made  by the intravenous  method,  which has  in  the main  been  em- 
ployed in  the  serotherapy  of Weil's  disease  since  May,  1916.  The 
number  of patients  treated  in  this  manner  in  our  clinic  from  May, 
1916,  to November,  1916,  was 41.  We found  that  the  intravenous 
injection  of immune  serum far  exceeds in potency the subcutaneous 
injection.  An explanation  of this finding may be sought in the fact 
that  the  therapeutic  effect of serum injected directly into  the blood 
stream is 500 times more potent than when it enters the organism by 
the subcutaneous route  (Berghaus). 
Experiments  to show the comparative  effects of the subcutaneous 
and  intravenous  administration  of serum in Weil's disease were un- 
dertaken  with  seven  rabbits,  the  animals receiving  0.5  to  1  cc.  of 
immune  serum  per  kilo  of  body weight.  At  various  intervals  the 
blood  of  the  animals  was  examined  for  spirocheticidal  and  spiro- 
chetolytic immune  bodies.  The  blood was taken  from  the  ear vein 
on the side opposite the one in which the  intravenous  injection  was 
made.  The results of these experimentsare  given in Table I. 
The immune  bodies could be demonstrated  as complete 5 minutes 
after  the intravenous  injection  of 0.5  cc.  of serum per kilo  of body 
weight,  while  with  the  subcutaneous  method  the  immune  bodies 
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could be detected  only 8 hours after the injection and were then not 
completely  absorbed.  This  passive  immunity  continued  for  3  or 4 
days.  Complete  immunity could not be obtained  in  man with  the 
use of the small dose injected subcutaneously, but when larger doses 
TABLE  I. 
Immune Bodies i,n Rabbits I~ected with the Blood of Patients Having Well's Disease. 
6  z 
1 
2 
3 
4 
5 
6 
7 
Method of 
injection. 
Intravenous. 
Subcutaneous. 
c( 
Intravenous. 
2,500 
cc.  co.  gin. 
1.0  2,500  / 
1.0  2,100[ 
0.5  3,400/ 
.Ss[  0.5  3,100  / 
.1  1.0  3,100[ 
4  0.5  F  ,900 / 
Pfeiffer's phenomenon. 
---~-ft  e~ion. 
Min,  tt:s.  I  Days. 
[ 
tiiiit t;i/isi il 
Titer of Serum Employed in the Experiments. 
0.001 
0.005 
Pfeiffer's phenomenon. 
No. of spirochetes• 
Liver  emulsion  (10  spi- 
rochetes per field) 1 cc. 
Course of disease. 
Died 5th day of icterus. 
"  16th  day  without 
icterus.  Autopsy neg- 
ative. 
Remarks. 
Control  died 4th day of 
icterus. 
-- indicates no immune bodies;  +  immune bodies complete;  ~- immune bodies 
incomplete. 
were given a  complete passive immunity was attained also with the 
subcutaneous method. 
The sera used were obtained from horse's blood as follows: No.  2, 
February  26,  1916;  No.  6,  August  7;  No.  7,  August  7;  and  No.  8, 
August  19.  One  of  the  horses  was  immunized  from  the beginning R.  INADA~  Y.  IDO~  R.  HOKI,  H.  ITO~  AND  H.  WANI  285 
with  a  living  culture  of Spirochceta  icterohcemorrhagioe; four  others 
received first an  inoculation  of the killed  ctflture,  followed later  by 
the living culture.  The latter procedure can be more readily carried 
out.  The  animal  receiving  the  living  culture  showed  on  the  7th 
day  a  temperature  of  39°C.  All  the  horses  were  immunized  by  a 
uniform procedure. 
Titer.--The  titer of the immune serum was determined by testing 
TABLE  II. 
Titer  of Serum. 
No. of 
senlm. 
Pfeiffer's phenomenon. 
Amount 
~f  serum. 
cc. 
0.005 
0.01 
0.01 
0.01 
0.03 
0.01 
No. of spirochetes. 
Liver  emulsion  (10 
per field) Icc. 
Liver  emulsion  (10 
per, field) 1 cc. 
Liver  emulsion  (I0 
per field) 1 ec. 
Liver  emulsion  (10 
per field) 1 cc. 
Course of disease. 
Died  12th day of  ic- 
terus. 
Died  18th day  with- 
out  icterus.  Au- 
topsy negative. 
Well  for  more  than 
a month. 
Died  10th  day  of 
ictems. 
Well for more than a 
month. 
Well for more than a 
month. 
Remarks, 
Control  died  4th  day 
of icterus. 
Control  died  4th  da~ 
of ictems. 
Control  died  4th  day 
of icterus. 
I Control  died  4th  day 
of icterus. 
the  quantity  which  would  protect  a  guinea  pig  weighing  200  gin. 
against infection from 1 cc. of pure culture containing  10 spirochete  s 
1 
per  field (Leitz r~  oil immersion, ocular 3).  The spirocheticidal titer 
of the serum was 0.01  and 0.03 cc.; it has been found that a  titer Of 
0.01 cc. suffices for the serotherapy of Weil's disease.  Table II shows 
the spirocheticidal  and  spirochetolytic effects of the immune  sera. 
The experiments were made with sterile sera without preservative 
(phenol).  As shown in Table II, Sera 2, 6, and 8 were more effective 
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Dose.--As  a rule, 60 cc. of serum were injected intravenously, irre- 
spective of the severity of illness, sometimes the entire quantity being 
given within 24 hours; or 40  cc. in a  day, and the remaining 20  cc. 
the following day; or 20 cc.  daily for 3 successive days.  We cannot 
at present state definitely which procedure is to be preferred, and in 
order to determine this point, it will be necessary to make observa- 
tions on a larger number of patients than is  here presented.  In any 
case, it is  clear  that the dose depends upon  the severity of the dis- 
ease.  The entire amount of 60  cc.  is  not needed in  the  treatment 
of the less severe cases, although this quantity is always put up for 
an individual dose.  In milder cases,  the injection of from 20  to 40 
cc.  of serum is sufficient. 
As is  the usual  custom,  the  serum was introduced into  the vein 
of the arm.  Previous to the injection 2  to 3  cc.  of serum were in- 
jected  subcutaneously into  the  chest  or  the  thigh  of  the  patient. 
The arm injection was then made 2 or 3 hours later, the serum being 
permitted to run in slowly, allowing 5  minutes for the introduction 
of 20 cc.  The serum should be warmed to body temperature  before 
use. 
Day of Injection.--This  has an important bearing on the course of 
the disease.  As already emphasized, the action of the immune serum 
is spirocheticidal and spirochetolytic.  The best results are obtained 
when  the injection is  made at  an  early stage  of  the  disease.  The 
question now arises: Up to what day of illness may the injections be 
continued with success?  This period can be determined by studying 
(1)  the infectivity of the patient's blood for guinea pigs,  (2)  the dis- 
tribution of the spirochetes in the organs at various stages,  and  (3) 
from  clinical  observations  of  patients  receiving  the  intravenous 
treatment.  Table  III gives  the infectivity of the blood on various 
days of the disease.  It is based on 42 cases treated recently, and 69 
older  cases.  It  will  be  observed  that  the  infectivity diminishes 
gradually in the course of the disease.  On the basis of these findings 
it would  seem  that  the intravenous injection is  effective up  to  the 
5th day. 
The investigations of Kaneko and Okuda concerning the distribution of spiro- 
chetes in the organs in Well's disease indicated that the liver harbors few or 
wholly degenerated forms on the  7th day.  In two patients  on whom a post- R. II~ADA~ Y. IDO~ R. IIOKI, H. ITO, AND  H. WAI~I  287 
mortem examination was made on the 6th day, spirochetes were found in mod- 
erate  numbers,  th;ough not so numerously  as in  the guinea pig.  According to 
thi~, as already stated, we may expect the intravenous injection to be successful 
up to the 5th day.  From our clinical observations, an undoubted effect can be 
obtained up to the 6th day of illness,  ,We had few cases of this kind, however. 
Four patients  received the intravenous injection on  the 3rd  day, 
9 on the 4th, 6 on the 5th, and 5 on the 6th day.  Patients admitted 
at  a  later  stage  received an initial  intravenous  injection,  not  fol- 
TABLE III. 
Infection  Experiments  on Guinea Pigs  w~th the  Blood of Patients  Ha~ing  Weil's 
Disease. 
~  .~  ~  ~  ~  ~  ~  ~  .~  ~.~ 
2  4  4  0  100.0  0  0  0  0  4  4  0  100.( 
3  10  10  0  ~00.0  4  4  0  100.0  14  14  0  100.( 
4  13  13  0  100.0  9  9  0  100.0  22  22  0  100.~ 
5  12  11  1  91.7  6  5  1  83.3  18  16  2  88. 
6  14  12  2  85.7  5  2  3  40.0  19  14  5  73. 
7  8  4  4  50.0  7  3  4  42.9  15  7  8  46.' 
8  4  0  4  0  3  1  2  33.3  7  1  6  14.2 
9  1  1  0  100.0  5  0  5  0  6  1  5  16." 
10  0  1  0  1  0  1  0  1  0 
11  0  1  0  1  0  1  0  1  0 
12  1  0  1  0  1  0  1  0  2  0  2  0 
18  1  0  1  0  1  0  1  0 
19  1  0  1  0  1  0  1  0 
Total  No. 
of cases...  69  42  111 
lowed by others.  12 of the patients showed no icterus on admission, 
although 4 had a  slightly yellowish pigmentation of the conjunctivae. 
Of these 12 patients, 6 failed to develop'icterus in the further course 
of  the  disease.  Classified  according  to  the  severity of illness,  we 
treated 6  slightly ill,  including atypical cases,  9  moderately ill,  and 
26  severe cases.  At the  time  that  the intravenous  treatment was 
being administered, we had in  the clinic 11  other  patients  who  re- 288  INTRAVENOUS  SEROTHERAP¥  OF  WEIL~S  DISEASE 
ceived  no  serum  treatment;  i.e.,  4  atypical  cases,  1  slightly  ill,  and 
6  moderately  ill.  There  were  no severe cases among  them.  It  will 
be  noted  that  the serum was administered  in the  main only  to  those 
who  were  severely  or moderately  ill. 
Age.--We  treated  9  patients  between  the ages of 16 and  20  years, 
9  between  21  and  30,  6  between  31  and  40,  10  between  41  and  50, 
4  between  51  and  60,  and  3  who  were  over  60  years  of  age.  We 
desire  to  add  here  that  our patients,  in addition  to  the  serotherapy, 
received  the  benefit  of  the  other  usual  methods  of  treatment  in 
Well's  disease;  i.e.,  the  intravenous  injection  of  Ringer's  solution 
and  the  subcutaneous  administration  of  camphor  and  cocaine. 
Spirocheticidal  and Spirochetolytic Effect of the Immune Serum Injected 
Intravenously. 
The  spirochetolytic  and  spirocheticidal  effects of the  serum  can  be 
most  readily  shown  when  the  spirochetes  are  demonstrable  in  the 
peripheral  blood  by  dark-field  illumination.  In  that  case  no  infec- 
tion  experiments  need  be  made.  Up  to  the  present  time,  however, 
we have  observed  this  to  be  true  in  only 2  out of 100  cases.  These 
2  cases  are  discussed  below. 
Case 1.--M.,  male;  age 47  years.  The  patient  was admitted  to  the  clinic 
on November 4,  1916, on the 3rd day of illness.  This was a severe case.  The 
blood  showed  by dark-field  illumination  1 spirochete  in from 70 to  140 fields. 
1 hour after  the intravenous injection of Serum 6,  no spirochetes  could be de- 
tected in two preparations.  Blood was then withdrawn from the arm vein, and 
two guinea  pigs  received  each  an intraperitoneal  injection of  1 cc.  of  the pa- 
tient's blood.  The animals became ill and showed typical symptoms 1 or 2 days 
later than the control animals, which had received blood withdrawn prior to the 
injection  of serum.  Although  no  spirochetes  were  found in  two preparations, 
the blood was still infectious. 
Case 5.--N.,  male; age 65  years.  He  became  suddenly ill  on  May 1,  1916, 
and was admitted to the clinic on May 4, the 4th.day of illness.  We were able 
to  demonstrate  numerous  Spirochceta icterohcemorrhagice  in  the  blood  by dark- 
field  illumination  in 14 to  16 specimens of 65  to 70 fields  each.  As a rule, spi- 
rochetes are not readily found in fresh preparations.  The findings of spirochetes 
before and after serum injections were as follows: 
2 p.m.  Spirochetes in the blood, 14 to 16 in 65 to 70 fields. 
3 p.m.  17 cc. of Serum 2 injected subcutaneously. 
6 p.m.  14 to 16 spirochetes in 65 to 70 fields. R.  INADA, Y.  IDO, R.  HOKI, H.  ITO, AND  H.  WANI  289 
7 p.m.  10 to 16 spirochetes in 65 to 70 fields. 
8 p.m.  20 cc. of Serum 2 injected intravenously. 
10 p.m.  No spirochetes in'2 preparations. 
12 m.  No spirochetes in 3 preparations. 
1 a.m.  2 cc. of patient's  blood injected intraperitoneally into a guinea pig, 
which remained well (May 14). 
1.30 a.m.  No spirochetes in 1 preparation. 
8.30 a.m.  3 cc. of patient's blood injected intraperitoneally into a guinea pig, 
which remained well. 
2  hours after the intravenous injection of serum in Case 5, we were 
unable to find any microorganisms.  Thls demonstration of the spi- 
rocheficidal and spirochetolytic action of the immune serum in man 
exactly parallels the results obtained with guinea  pigs.  The patient 
died, however, a£ 5.30 p.m. on the following day.  ' But the unexpected 
results obtained in this case induced us in later cases to employ only 
the ~travenous injection method. 
The experiments demonstrate clearly the spirocheticidal and spiro- 
chetolytic action of the immune serum, which is.capable of destroying 
the spirochetes in the blood stream within a  short period of time. 
In the other thirty-nine cases spirochetes could not be readily dem- 
onstrated  in  the  blood  by dark-field illumination.  Hence we  con- 
ducted infection experiments before and after serum injection, simi- 
lar  to  those made with  the  subcutaneous serum  cases  (Table  IV). 
Table  V  gives  the  results  of  the infection experiments,  the  serum 
administered, and the day of illness when the blood was taken.  We 
have omitted from the table the cases which were negative with the 
use of blood drawn before serum was injected. 
The infection experiments were all negative following the injection 
of 20 cc. of Serum 2.  With Serum 6, only one experiment was posi- 
tive.  In  this instance  the  animal was inoculated 1  hour after the 
injection  of  the  patient.  It  appears  that  Sera  2  and  6  possessed 
markedly potent spirocheticidal and spirochetolytic properties, while 
No.  7  was less  effective; the  titer of the latter  serum was 0.03  cc. 
Although the infection experiments were positive with blood  taken 
after the injection of Serum 7, the animals became typically ill much 
later  than  the  animals receiving blood  drawn  before  the  injection. 
The difference in the duration of the life of the animals in the two 
groups was from 3  to 7 days, as in Cases 10,  11,  12,  13,  19,  and 25. 290  INTRAVENOUS  SEROTHERAPY  OF  WEIL~S  DISEASE 
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Cases  1  and  4  are  exceptions.  It  is  evident  that  the  serum  was 
potent after 3 hours, although it was incapable in this short period of 
time of destroying completely the spirochetes contained in the blood. 
This is true also of Serum 8. 
The  time elapsing between the injection of serum and  the  with- 
drawal of blood varied from 1 to  18 hours,  the usual interval being 
3 hours.  Table VI gives the infection experiments carried out with 
TABLE V. 
Infection Experiments witl, Patients' Blood Withdrawn before and after Intravenous 
Injection of 20 Cc. of Serum. 
Positive Infections. 
Day of illness. 
3  4  5  6  7  No of serum. 
Before 
injec- 
tion. 
1 
3 
After 
injec- 
tion. 
Be.fore 
lnjec- 
tlon. 
4 
1 
3 
1 
After 
injec- 
tion. 
0 
0 
3 
1 
Before 
injec- 
tion. 
1 
3 
1 
After 
injec- 
tion. 
0 
0 
1 
Before 
injec- 
tion.. 
1 
i 
1 
1 
After 
injec- 
tion. 
0 
0 
I 
0 
Before 
injec- 
tion. 
2 
1 
After 
injec- 
tlon. 
0 
0 
TABLE VI. 
Infection  Experiments with Blood Withdrawn after Serum Injections. 
Time between serum  injection  Infection experiments before  Infection experiments after serum 
and withdrawal of blood,  serum injection,  injection. 
]~r$. 
1-3 
Over 5 
q- 19. 
+  5 
--  13 
+'6 
--  4 
+  1 
blood  withdrawn  after  serum  injection.  These  results  show  that 
serum having a  fiter of 0.01  cc., given intravenously in doses of 20 
cc.,  after 3  hours  destroys completely spirochetes contained in  the 
peripheral  blood,  which then is  incapable  of infecting guinea  pigs. 
While with the use of sera having a titer of 0.03 cc., we found 3 hours 
after  injection  incomplete destruction  of  spirochetes  in  the blood, 294  INTRAVENOUS  SEROTttERAP¥  OF  WEIL~S  DISEASE 
the  animals  became  typically  ill  later  than  the  controls.  It  would 
appear,  then,  that  the  spirochetes had  become reduced  in  number or 
had  lost  some of their  virulence. 
Behavior o'f the Immune Bodies in the Blood. 
Experiments  were  conducted  with  the  blood  of  twenty  patients. 
Owing  to  a  shortage  of guinea  pigs,  we  were  not  able  to  inject  the 
animals immediately after withdrawal of the blood, and the fluid was 
placed  in  the  refrigerator  until  it  could  be  used.  Unfortunately, 
most  of  these  specimens  became  contaminated.  The  results  of  our 
investigation  for the  presence  of immune  bodies  in  the  blood  during 
the course of the disease,  after intravenous  injection  of immune sera, 
are  shown in  Table VII. 
The  immune  bodies  appear in  the  blood  much  earlier  with  intra- 
venous  than  with  subcutaneous  injections.  They  are  present  as 
TABLE  VII. 
Appearance of Immune Bodies in the Serum  of Intravenously Injected Patienls. 
Case No. 
8 
4 
2 
11 
10 
7 
6 
14 
38 
19 
15 
23 
24 
21 
20 
30 
33 
28 
29 
34 
"Day of ill- 
injected. 
4 
3 
3 
4 
4 
4 
4 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
7 
7 
8 
6 
±(4- 7) 
4- 
Day of illness when blood was withdrawn. 
4- 
4- 
±(4- 
7  8 
+ 
+ 
+ 
+ 
4) 
+ 
+ 
+ 
9  10 
÷ 
-q- 
+ 
4- 
jr 
q- 
12 
+ 
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early  as  the  8th or 9th  day, which  does  not,  as a  rule, occur when 
the patient has received no serum treatment.  They may be observed 
after the introduction of 60 cc. of immune serum. 
In  one of  the  cases  referred  to  the  immune  bodies  appeared  as 
early as  the 6th day, before the administration  of serum was begun. 
It  is possible that  in  this  instance  an error  has been made  in  com- 
puting  the  day  of  illness,  inasmuch  as  we  have  never  observed a 
similar  result  with  other  non-serum-treated  cases. 
Mortality. 
The total mortality with the use of the intravenous  injections  was 
23.7 per cent.  Of forty-one patients under observation, twelve died. 
We have not included in our tabulations a patient who after recovery 
from the disease died on the 55th day from complications,  a  patient 
admitted to the clinic in moribund condition who died after 29 hours 
(numerous spirochetes could be demonstrated in the blood), and an- 
other,  admitted  when  moribund,  who  died  after  31  hours.  The 
mortality "of  patients  receiving  no  serum  was  30.6  per  cent.  In 
the  subcutaneously  injected  patients,  the  percentage  was  17.3. 
This  low  mortality  in  the  case  of  the  subcutaneously  injected 
patients is attributable  to the fact that in this group, which entered 
before the 'Sth  day of illness,  only five patients  were over 40  years 
of age, while in the group of intravenously injected patients,  twelve 
were over that  age. 
Since in the moderate and  slight forms of Weil's disease death  re- 
sults  from  complications,  we  shall  consider particularly  the  severer 
cases of the disease.  As the  serum is  effective only  when  adminis- 
tered in  the  initial  stage,  we have  not considered in our  study  pa- 
tients  admitted  after  the  6th  day.  The  mortality  of patients  who 
were admitted  before the  7th  day and  received  no  serum  was 57.1 
per  cent, ~of  the  subcutaneously injected  patients  40  per  cent,  and 
of the intravenously injected patients  38.5 per cent. 
It  is  clear  that  the  total mortality  figures,  particularly  the  mor- 
tality of the severer cases, is considerably lower in the case of intra- 
venous  and  subcutaneous  serum  administration  than  in  the  non- 
serum-treated  cases. 296  INTRAVENOUS  SEROTIIERAPY  OF  WELL'S  DIsEAsE 
In judging the results, one should take into account factors which 
strongly  influence  the  prognosis.  Among  these  factors  must  be 
counted the age of the patient, the severity of the illness, the season 
of its  occurrence,  and  above  all  the  day of illness on which  serum 
was  first administered.  One  must  also  consider whether  the  cases 
occur in epidemic form or sporadically.  The difficulty of estimating 
the results is  further increased by the fact that  often at  the onset 
it is not possible to judge precisely the degree of severity of the dis- 
ease,  while on  the 6th or  8th day an error in prognosis is  unusual. 
Table  VIII shows  the influence of the  age of the patient upon  the 
prognosis. 
TABLE VIII. 
Mortality and Age. 
Age. 
yrs. 
Up to 20 
21-30 
31--40 
41-50 
51-60 
Over 60 
Without serum treatment. 
Inada. 
per cent 
12.5 
21,0 
23.5 
21.4 
75.0 
50.0 
Nagao. 
p~r cent 
60.0 
17.9 
20.0 
35.0 
50.0 
"75.0 
Intravenous serum 
treatment. 
~r cent 
0 
12.5 
0 
42.8 
33.3 
I00.0 
Of 21 patients less than 40 years old, admitted from the 3rd to the 
7th  day  of  illness,  who  were  treated  by  intravenous  injections of 
serum, only  1  died.  This  was a patient  admitted on  the  7th day. 
The 21  cases included 4  slightly ill, 7 moderately ill, and 10 severely 
ill patients.  Of the 12 patients over 40 years of age--2 slightly ill and 
10  severely ill--7  died.  Prior to  the age of 40,  a  good result is in- 
sured from the serum injectiohs, but after 50  the outlook is not fav- 
orable; the older persons constitute, in fact, the severest cases of the 
disease.  When we compare  10  severe cases below 40  years with 10 
above  that  age,  we find among the first only 1  death as  against  7 
deaths  in  the  older  group.  It is  evident  that  the  years  above  40 
exert  an  unfavorable influence  on  the  prognosis  of  Well's  disease, 
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Effect of Intravenous  Serotherapy  on the Spirochetes in the Organism. 
The  spirochetolytic  action  of  the  immune  serum  upon  the  spiro- 
chetes in the human  body is more pronounced with the intravenous 
than  with  the  subcutaneous  injection.  Kaneko  and  Okuda  have 
studied this phase of the subject.  * 
Effect of Serotherapy  upon the Symptoms and Course of Well's Disease. 
Severity  of  Illness.--When  the  serum  is  administered  early,  the 
disease  appears  to  assume  a  milder  form.  As. already  stated,  it  is 
difficult at the be.ginning  to judge the precise degree of illness.  We 
observed  one  patient  moderately  ill  and  another  slightly  ill,  who 
after  the  serum  injection  could be grouped with  the  atypical  cases. 
It is, however, not possible to assert that this change is wholly attrib- 
utable to the serum; it may be that  the disease in these cases would 
have  run  a  less  severe course without  the  administration  of serum. 
But when  we study the  influence  of the intravenous injection  upon 
the different symptoms, we find that  on the whole they are consid- 
erably diminished  and shortened in duration. 
Fever  appears  not  to be influenced  by the  serum  to  any  extent, 
even in  cases where serum is administered  early in the  disease.  In 
fact we often observed a rise in temperature after an injection, though 
it is  not possible to' say that this was due to the action of the  serum. 
The  immune  serum  has  a  favorable effect on  the  duration  of the 
icterus.  The exact time of disappearance  cannot be definitely stated 
on the basis of an examination  made  of the skin and mucous mem- 
branes,  inasmuch  as  anemia  usually  follows  recovery.  We  have, 
therefore, taken as an index Gmelln's urine test, which has been used 
in our clinic during the past 10 years.  Without serum treatment,  the 
icteric condition usually continues for a period of 20 days or more in 
the severe cases, sometimes as long as 30 days; and in the moderately 
ill 14 to 30 days, occasionally more than that time.  In the cases re- 
ceiving subcutaneous serum  treatment,  the icterus  continued  for an 
equal  length  of time.  No  definitely favorable  effect was observed, 
even  in  the  cases  receiving  an  injection  as  early  as  the  3rd or 4th 
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day of illness.  On  the other  hand,  the icterus  of the  intravenously 
treated  patients  in  most  cases  disappeared  within  20  days,  in  the 
earliest case on the  13th day.  No such finding was ever observed in 
the  non-serum-treated  cases  or  in  those  receiving  subcutaneous  in- 
jections.  Of  the  severe cases  receiving  the  intravenous  injection 
prior  to  the  6th  day,  in  only two did  the icterus  last more  than  20 
days.  The  longest period  was  12  to  14  days in  moderately  severe 
cases.  When  the  injection  of serum  is  deferred  until  after  the  6th 
or  7th  day,  the  icteric  condition  Will continue  as  long  as  it  would 
if no serum had  been given.  We cannot state definitely whether an 
injection  made on  the  1st or  2nd  day is  capable of suppressing  the 
icterus  completely,  but  this is probable.  Of the eight patients  who 
received  serum  treatment  on  the  3rd  or  4th  day  and  at  that  time 
showed no signs of icterus,  three remained without jaundice through- 
out.  In  any  event we may say that  the  duration  of  the  icterus  is 
shortened  considerably  when  the  intravenous  injections  are  given 
early  in  Weil's  disease.  The  intensity  of  the  icterus  in  most  cases 
is  greatly  diminished  by the  intravenous  injections  (Tables  IX,  X, 
and  XI). 
The  serum  has  likewise  a  decided  influence  upon  hemorrhages. 
This  was observed to a  slight  extent also with  the  subcutaneous in- 
jections.  As a rule, cutaneous hemorrhages continue, but they are less 
pronounced  in  character.  The  percentage  of  petechi~e  in  the  pa- 
tients  receiving  intravenous treatment  was  70.7,  while in  those  re- 
ceiving no  serum  it was  72.2.  Although  there  is little  difference in 
the figures,  the duration of this symptom in the first group was con- 
siderably  shorter.  In  half  of  the  non-serum-treated  cases  the  pe- 
techiae  continued  for  10  days,  while  in  the  cases  which  received 
serum  intravenously  (admitted  from  the  1st  to  the  6th  day  of ill- 
ness)  only a  third  showed this symptom for more than  9 days.  The 
number  and  size of the petechial  spots were also reduced.  Hemor- 
rhage  from' the  nose  occurred  also  with  serum  treatment,  but  the 
percentage was somewhat smaller;  that is, 29.3 against 32.7 per cent. 
Hemorrhages  from  the  mucous  membranes,  gums,  and  tongue,  and 
hematoma of the buccal mucosa continued to occur.  In the intrave- 
nously  treated  cases  the  proportion  was  41.5 per  cent,  in  the non- 
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was given early,  within the  first  6  days,  the  percentage was 30.6. 
This is true of intestinal hemorrhages, which may be reduced one-half 
by the intravenous injections.  Table XII gives in  percentages the 
TABLE IX. 
Duration  of lcterus with Intravenous  Serum Injection. 
Day of  illness  when 
serum was injected.  Degree of illness.  Duration of icterus. 
3 
(four cases). 
4 
(five cases). 
5 
(five cases). 
6 
(six cases). 
7 
(six cases). 
8 
(two cases). 
9 
(two cases). 
Total 30 
Atypical. 
Severe. 
Atypical. 
Severe. 
Moderately severe. 
Severe. 
Moderately severe. 
Severe. 
Moderately severe. 
Severe. 
Atypical. 
Slight. 
Moderately severe. 
Slight. 
Moderately severe. 
Severe, 
Severe. 
Moderately severe. 
Severe. 
Moderately severe. 
Severe. 
days 
Without icterus.  Icterus only of 
conjunctive bulbi. 
Without icterus. 
15 
14 
15 
23 
Without icterus. 
8 
12 
16 
21 
Without icterus.  Icterus only of 
conjunctive bulbi. 
11 
12 
13 
18 
16 
14 
16 
17 
23 
30 
16 
28 
13 
23 
Moderately severe. 
Severe. 
13 
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hemorrhages  occurring  in  the  non-serum-treated  cases,  the  intra- 
venously  treated  cases,  and  of  the  latter  those  receiving  serum  in- 
jections  at an early  stage.  The  table also  shows the percentages  of 
hematemesis  and  epistaxis. 
TABLE  X. 
Duratiot~ of Icterus with Subcutaneous Serum Injection. 
Day of illness when 
serum was injected.  Degree of illness.  Duration o~ icterus. 
days 
3 
(one case).  Atypical.  4 
4  Severe.  22 
(one case). 
Severe.  16 
5 
(three cases).  Moderately severe.  20 
Severe.  24 
6 
(six cases). 
7 
(three cases). 
8 
(five cases). 
Slight. 
Severe. 
Moderately severe (approaching 
slight form). 
Severe. 
Moderately severe. 
Severe. 
Severe. 
4¢ 
Slight. 
Moderately severe (approaching 
slight form). 
Moderately severe. 
"  "  (approaching 
severe form). 
14 
18 
20 
20 
29 
33 
20 
24 
30 
10 
20 
24 
25 
26 
9 
Severe.  20  (one case). 
13 
Severe.  17 (died on 34th day).  (one case). 
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From  the  above  considerations  we  may  conclude  that  the  early 
intravenous  injection of immune  serum has  a  decidedly favorable in- 
fluence  upon  the  hemorrhagic  tendency  of  Well's disease,  and  par- 
ticularly upon  hemorrhages  from  the mucous  membranes. 
TABLE  XI. 
Duration of Icterus without Serum Treatment  in  Thirty-Six Cases. 
Degree  of  illness. 
Atypical. 
Slight. 
Moderately severe. 
Slight. 
Moderately severe. 
Severe. 
cc 
Moderately severe. 
Slight. 
Moderately severe. 
Severe. 
cl 
~c 
~c 
c~ 
Moderately severe. 
lc 
cl 
Severe. 
o 
Moderately severe. 
lc  c~ 
Severe. 
"  ,  (approaching severe form). 
cc 
¢c 
¢c 
"  (approaching severe form). 
Duration  of  icterus. 
days 
Ictems  only  of  conjunctiva  bulbi. 
5 
11 
12 
14 
14 
17 
17 
18 (died on 18th day). 
2O 
20 
21 
22 
22 
24 
24 
24 
25 
25 
22 
25 
25 
26 
28 (had beri-beri). 
29 
30 
30 
30 
31 
34 
37+ 
37+ 
38+ 
24+ 
24+ 
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TABLE  XII. 
Percentage of Hemorrhages in the Serum-Treated  and Non-Serum-Treated  Cases. 
Symptoms. 
FIemorrhages from tongue and mouth 
Intestinal hemorrhages 
[Iematemesis.. 
Bloody stools 
Petechi~e ... 
Epistaxis 
3omplications--suppurative processes 
Without serum 
treatment. 
per  cent 
43.5 
30.2 
11.3 
15.1 
72.2 
32.7 
24.0 
Intravenous 
serum 
treatment. 
~eT cenl 
41.5 
22.0 
9,7 
7.3 
70.7 
29.3 
14.6 
Intravenous 
~erumtreatmenl 
(26  eases 
admitted from 
.-6 days). 
per  cent 
30.6 
15.3 
7.6 
7.6 
69.2 
4.9 
We have not observed a decidedly favorable influence of the serum 
upon  the pulse,  although arrhythmia was a  less frequent symptom. 
It  occurred  in  20  per  cent  of  the  cases,  while  in  the  non-serum- 
treated cases the figure was 50 per cent. 
Complications  such  as  suppurative  processes--parotitis,  skin  ab- 
scesses-were found in  14.6 per  cent, in patients admitted from the 
3rd to the 6th day only in 4.9 per cent, and in patients receiving no 
serum  treatment in  24  per  cent  of  the  cases.  Thus  these  compli- 
cations are greatly reduced with the early use  of  the  serum. 
Summarizing the observations on such symptoms as hemorrhage, 
particularly  of  the  mucous  membranes,  heart  rhythm,  and  sup- 
purative  processes,  which play a  large  part  in  the  outcome of  the 
disease,  we are justified in  saying that  the intravenous injection of 
immune serum has a  definitely beneficial effect. 
The after-fever was found to occur somewhat more frequently--in 
34.1 per cent--while without serum treatment it occurred in only 28.2 
per cent.  The greater frequency of this symptom is probably refer- 
able to the fact that the most severely ill patients who recover from 
the  disease  are  included in  this  category.  As  the  time of greatest 
mortality of Weil's disease lies between the 8th and the 18th days, and 
the after-fever, as a rule, does not begin until the 13th or 15th day, it 
is  evident  that  this  symptom does  not  usually occur  in  the  cases 
ending  fatally.  The percentage  of  after-fever is  found  to  increase 
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On  two  occasions  following  the  injection  of  Serum  7,  and  once 
after  Serum  2,  the  patients  had  chills  followed by  a  rise  in  tem- 
perature.  Serum rash occurred three times after the administration 
of Serum 2.  There were no anaphylactic manifestations. 
Among  18  patients  who  returned  for  examination  after  several 
months we found 8 who showed more or less marked ocular disturb- 
ances.  These  18  cases  comprised  10  severe,  5  moderately severe, 
and 3 atypical forms of the disease.  The 8 patients showing ocular 
disturbances were as follows: 5  from the severely ill group,  1 from 
the moderately ill, and 2 from the atypical group.  1 patient showed, 
on examination'in the ophthalmologic clinic, iridocyclitis, hypopyon 
of the right eye, and opacity of the vitreous humor; in another only 
the last  symptom was  present.  These after-effects seem to  occur 
more frequently in the severe types of the disease.  We cannot say 
at  this  time  to  what  extent  the  sequela~  are  influenced by  serum 
treatment. 